Cargando…

Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening

High-throughput (HT) RNA interference (RNAi) screens are increasingly used for reverse genetics and drug discovery. These experiments are laborious and costly, hence sample sizes are often very small. Powerful statistical techniques to detect siRNAs that potentially enhance treatment are currently l...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Wiel, Mark A, de Menezes, Renée X, Siebring-van Olst, Ellen, van Beusechem, Victor W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654870/
https://www.ncbi.nlm.nih.gov/pubmed/23819807
http://dx.doi.org/10.1186/1755-8794-6-S2-S1
_version_ 1782269782238691328
author van de Wiel, Mark A
de Menezes, Renée X
Siebring-van Olst, Ellen
van Beusechem, Victor W
author_facet van de Wiel, Mark A
de Menezes, Renée X
Siebring-van Olst, Ellen
van Beusechem, Victor W
author_sort van de Wiel, Mark A
collection PubMed
description High-throughput (HT) RNA interference (RNAi) screens are increasingly used for reverse genetics and drug discovery. These experiments are laborious and costly, hence sample sizes are often very small. Powerful statistical techniques to detect siRNAs that potentially enhance treatment are currently lacking, because they do not optimally use the amount of data in the other dimension, the feature dimension. We introduce ShrinkHT, a Bayesian method for shrinking multiple parameters in a statistical model, where 'shrinkage' refers to borrowing information across features. ShrinkHT is very flexible in fitting the effect size distribution for the main parameter of interest, thereby accommodating skewness that naturally occurs when siRNAs are compared with controls. In addition, it naturally down-weights the impact of nuisance parameters (e.g. assay-specific effects) when these tend to have little effects across siRNAs. We show that these properties lead to better ROC-curves than with the popular limma software. Moreover, in a 3 + 3 treatment vs control experiment with 'assay' as an additional nuisance factor, ShrinkHT is able to detect three (out of 960) significant siRNAs with stronger enhancement effects than the positive control. These were not detected by limma. In the context of gene-targeted (conjugate) treatment, these are interesting candidates for further research.
format Online
Article
Text
id pubmed-3654870
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36548702013-05-20 Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening van de Wiel, Mark A de Menezes, Renée X Siebring-van Olst, Ellen van Beusechem, Victor W BMC Med Genomics Research High-throughput (HT) RNA interference (RNAi) screens are increasingly used for reverse genetics and drug discovery. These experiments are laborious and costly, hence sample sizes are often very small. Powerful statistical techniques to detect siRNAs that potentially enhance treatment are currently lacking, because they do not optimally use the amount of data in the other dimension, the feature dimension. We introduce ShrinkHT, a Bayesian method for shrinking multiple parameters in a statistical model, where 'shrinkage' refers to borrowing information across features. ShrinkHT is very flexible in fitting the effect size distribution for the main parameter of interest, thereby accommodating skewness that naturally occurs when siRNAs are compared with controls. In addition, it naturally down-weights the impact of nuisance parameters (e.g. assay-specific effects) when these tend to have little effects across siRNAs. We show that these properties lead to better ROC-curves than with the popular limma software. Moreover, in a 3 + 3 treatment vs control experiment with 'assay' as an additional nuisance factor, ShrinkHT is able to detect three (out of 960) significant siRNAs with stronger enhancement effects than the positive control. These were not detected by limma. In the context of gene-targeted (conjugate) treatment, these are interesting candidates for further research. BioMed Central 2013-05-07 /pmc/articles/PMC3654870/ /pubmed/23819807 http://dx.doi.org/10.1186/1755-8794-6-S2-S1 Text en Copyright © 2013 van de Wiel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
van de Wiel, Mark A
de Menezes, Renée X
Siebring-van Olst, Ellen
van Beusechem, Victor W
Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title_full Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title_fullStr Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title_full_unstemmed Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title_short Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening
title_sort analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput rna interference screening
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654870/
https://www.ncbi.nlm.nih.gov/pubmed/23819807
http://dx.doi.org/10.1186/1755-8794-6-S2-S1
work_keys_str_mv AT vandewielmarka analysisofsmallsampleclinicalgenomicsstudiesusingmultiparametershrinkageapplicationtohighthroughputrnainterferencescreening
AT demenezesreneex analysisofsmallsampleclinicalgenomicsstudiesusingmultiparametershrinkageapplicationtohighthroughputrnainterferencescreening
AT siebringvanolstellen analysisofsmallsampleclinicalgenomicsstudiesusingmultiparametershrinkageapplicationtohighthroughputrnainterferencescreening
AT vanbeusechemvictorw analysisofsmallsampleclinicalgenomicsstudiesusingmultiparametershrinkageapplicationtohighthroughputrnainterferencescreening